Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Andrea Paterson"'
Autor:
Roger Owen, Mark Cook, David Meads, David A Cairns, Christopher Parrish, Gordon Cook, Kwee Yong, Guy Pratt, Martin Kaiser, Karthik Ramasamy, Graham Jackson, Catherine Olivier, Amy Beth Coulson, Kara-Louise Royle, Anna Hockaday, Ruth de Tute, Bryony Dawkins, Mark Drayson, Jonathan Sive, Holger W Auner, Sergio Quezada, Lorna Barnard, Rhiannon Lambkin, Andrea Paterson, Mike Chapman, Rakesh Popat, Ceri Bygrave, Andrew Chantry, Samir Asher
Publikováno v:
BMJ Open, Vol 12, Iss 11 (2022)
Introduction Multiple myeloma is a plasma cell malignancy that accounts for 1%–2% of newly diagnosed cancers.At diagnosis, approximately 20% of patients can be identified, using cytogenetics, to have inferior survival (high-risk). Additionally, sta
Externí odkaz:
https://doaj.org/article/bf5f5424894a43a2927ade7759c778ff
Autor:
J. Sidney Ang, Martin N. Aloise, Diana Dawes, Maryn G. Dempster, Robert Fraser, Andrea Paterson, Paul Stanley, Adriana Suarez-Gonzalez, Martin Dawes, Hagit Katzov-Eckert
Publikováno v:
BMC Research Notes, Vol 11, Iss 1, Pp 1-5 (2018)
Abstract Objective A simple, non-invasive sample collection method is key for the integration of pharmacogenetics into clinical practice. The aim of this study was to gain samples for pharmacogenetic testing and evaluate the variation between dry-flo
Externí odkaz:
https://doaj.org/article/626c8179f91c49438d592775f4924cd7
Autor:
Kara-Louise Royle, Amy Beth Coulson, Karthik Ramasamy, David A Cairns, Anna Hockaday, Sergio Quezada, Mark Drayson, Martin Kaiser, Roger Owen, Holger W Auner, Gordon Cook, David Meads, Catherine Olivier, Lorna Barnard, Rhiannon Lambkin, Andrea Paterson, Bryony Dawkins, Mike Chapman, Guy Pratt, Rakesh Popat, Graham Jackson, Ceri Bygrave, Jonathan Sive, Ruth de Tute, Andrew Chantry, Christopher Parrish, Mark Cook, Samir Asher, Kwee Yong
Peer reviewed: True
INTRODUCTION: Multiple myeloma is a plasma cell malignancy that accounts for 1%-2% of newly diagnosed cancers.At diagnosis, approximately 20% of patients can be identified, using cytogenetics, to have inferior survival (high-
INTRODUCTION: Multiple myeloma is a plasma cell malignancy that accounts for 1%-2% of newly diagnosed cancers.At diagnosis, approximately 20% of patients can be identified, using cytogenetics, to have inferior survival (high-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c024a36191c37f158c659ee1de789437
https://www.repository.cam.ac.uk/handle/1810/343534
https://www.repository.cam.ac.uk/handle/1810/343534
Autor:
Samir Asher, Sian Faustini, Andrea paterson, Kara-Louise Royle, Amy Coulson, Lorna Barnard, Aleena Liaquat, Doina Levinte, Anna Hockaday, Catherine Olivier, David Cairns, Christopher Parrish, Gordon Cook, Graham Jackson, Michael Chapman, Martin Kaiser, Matthew Jenner, Ceri Bygrave, Jonathan Sive, Rakesh Popat, Guy Pratt, Alex Richter, Mark Drayson, Karthik Ramasamy, Kwee Yong
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S148-S149
Autor:
Martin Kaiser, Anna Hockaday, David A Cairns, J. Anthony Child, Walter M Gregory, John R Jones, Mark T. Drayson, Charlotte Bradbury, Zoe Craig, Graham Jackson, Gareth J. Morgan, Andrea Paterson, Matthew W Jenner, Gordon Cook, Faith E. Davies, Charlotte Pawlyn, Roger G. Owen
Publikováno v:
Blood. 136:1091-1104
Newly diagnosed multiple myeloma (NDMM) patients treated with immunomodulatory drugs are at high risk of venous thromboembolism (VTE), but data are lacking from large prospective cohorts. We present thrombosis outcome data from Myeloma IX (n = 1936)
Publikováno v:
Can J Psychiatry
Autor:
Rebecca Mottram, Matthew W Jenner, Martin Kaiser, Roger G. Owen, Charlotte Pawlyn, Andrea Paterson, Faith E. Davies, Mark T. Drayson, Gordon Cook, David A Cairns, Gareth J. Morgan, Graham Jackson
Publikováno v:
Blood. 134:604-604
Background Outcome varies considerably in newly diagnosed myeloma (NDMM), in particular in transplant eligible (TE) patients, ranging from a few years to decades. Autologous stem cell transplant (ASCT) remains the overall aim following induction ther
Autor:
Roger G. Owen, David A Cairns, Alina Striha, Mamta Garg, John R Jones, Matthew W Jenner, Mark T. Drayson, Graham Jackson, Kamaraj Karunanithi, Ceri Bygrave, Gareth J. Morgan, Cathy Williams, Charlotte Pawlyn, Martin Kaiser, Jindriska Lindsay, Gordon Cook, Andrea Paterson, Anna Hockaday, Nigel H Russel, Walter M Gregory, Faith E. Davies, Bhuvan Kishore
Publikováno v:
Blood. 132:122-122
Introduction Multi-agent induction chemotherapy followed by autologous stem cell transplant (ASCT) is a standard of care for younger patients with multiple myeloma, aimed at maximising the depth and duration of first response (PFS1). However, the dur
Autor:
Martin Dawes, Gideon Liknaitzky, J. Sidney Ang, Martin N. Aloise, Pieter R. Cullis, Adriana Suarez-Gonzalez, Andrea Paterson, Diana Dawes, Robert Fraser, Paul Stanley, Hagit Katzov-Eckert
Publikováno v:
CMAJ open. 4(3)
Background Inappropriate prescribing increases patient illness and death owing to adverse drug events. The inclusion of genetic information into primary care medication practices is one solution. Our aim was to assess the ability to obtain and genoty
Autor:
Philip G, Conaghan, Elizabeth M A, Hensor, Anne-Maree, Keenan, Ann W, Morgan, Paul, Emery, Andrea, Paterson
Publikováno v:
Rheumatology. 49:1894-1899
Current UK management of RA initially employs conventional DMARDs, with biological therapy reserved for DMARD-resistant RA patients with persistently high 28-joint disease activity score (DAS-28). The aim of this study was to examine the effect on pa